Altimmune (NASDAQ:ALT) Trading 5.3% Higher

Shares of Altimmune, Inc. (NASDAQ:ALTGet Free Report) traded up 5.3% during trading on Tuesday . The company traded as high as $7.53 and last traded at $7.52. 5,875,926 shares were traded during mid-day trading, an increase of 24% from the average session volume of 4,744,662 shares. The stock had previously closed at $7.14.

Analyst Upgrades and Downgrades

ALT has been the subject of a number of recent analyst reports. Guggenheim downgraded shares of Altimmune from a “buy” rating to a “neutral” rating in a report on Monday, April 29th. Piper Sandler restated an “overweight” rating and set a $25.00 price target on shares of Altimmune in a report on Friday. HC Wainwright restated a “buy” rating and set a $12.00 price target on shares of Altimmune in a report on Tuesday, May 14th. B. Riley restated a “buy” rating and set a $20.00 price target on shares of Altimmune in a report on Tuesday. Finally, JMP Securities cut their price target on shares of Altimmune from $25.00 to $24.00 and set a “market outperform” rating for the company in a report on Friday, May 10th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $18.80.

Get Our Latest Stock Report on Altimmune

Altimmune Price Performance

The company has a market capitalization of $525.37 million, a price-to-earnings ratio of -4.36 and a beta of 0.11. The business’s 50 day simple moving average is $7.11 and its 200 day simple moving average is $8.80.

Altimmune (NASDAQ:ALTGet Free Report) last posted its quarterly earnings data on Thursday, May 9th. The company reported ($0.34) EPS for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.02. The company had revenue of $0.01 million for the quarter. Altimmune had a negative net margin of 22,645.37% and a negative return on equity of 46.96%. During the same quarter in the prior year, the firm posted ($0.40) earnings per share. As a group, analysts expect that Altimmune, Inc. will post -1.34 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Timelo Investment Management Inc. boosted its holdings in Altimmune by 2,597.0% during the fourth quarter. Timelo Investment Management Inc. now owns 809,095 shares of the company’s stock worth $9,102,000 after buying an additional 779,095 shares in the last quarter. Farallon Capital Management LLC boosted its holdings in Altimmune by 1,282.4% during the first quarter. Farallon Capital Management LLC now owns 470,000 shares of the company’s stock worth $4,785,000 after buying an additional 436,000 shares in the last quarter. Lighthouse Investment Partners LLC purchased a new stake in Altimmune during the fourth quarter worth about $4,493,000. Knoll Capital Management LLC lifted its holdings in shares of Altimmune by 183.6% in the first quarter. Knoll Capital Management LLC now owns 567,219 shares of the company’s stock valued at $5,774,000 after purchasing an additional 367,219 shares in the last quarter. Finally, GSA Capital Partners LLP lifted its holdings in shares of Altimmune by 153.1% in the third quarter. GSA Capital Partners LLP now owns 445,868 shares of the company’s stock valued at $1,159,000 after purchasing an additional 269,676 shares in the last quarter. 78.05% of the stock is currently owned by institutional investors and hedge funds.

Altimmune Company Profile

(Get Free Report)

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.

Recommended Stories

Receive News & Ratings for Altimmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Altimmune and related companies with MarketBeat.com's FREE daily email newsletter.